A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated
1期
已完成
NCT04958252
| 适应症 | Healthy |
|---|
| 分期 | 1期 |
|---|
| 申办方 | Boehringer Ingelheim |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 56 人 |
|---|
| 干预（药物） | BI 1569912 |
|---|
| 开始日期 | 2021年8月5日 |
|---|
| 完成日期 | 2023年10月30日 |
|---|
| 结果公布日 | 2026年5月22日 |
|---|
摘要
The main objectives of this trial are to investigate safety and tolerability of BI 1569912 in healthy male Japanese subjects following oral administration of single rising doses and multiple doses. Secondary objective is the exploration of pharmacokinetics (PK) of BI 1569912.
SRD Part - Number of Subjects With Drug-related Adverse Events
From drug administration plus 48 hours (residual effect period (REP)), or 12:00 a.m. on day after subject's trial termination date, whichever occurs first, up to 48 hours. · Participants
| SRD Part - Placebo | 0 Participants |
|---|
| Single-rising Dose Part - BI 1569912 2.5 mg | 0 Participants |
|---|
| Single-rising Dose Part - BI 1569912 5 mg | 0 Participants |
|---|
| Single-rising Dose Part - BI 1569912 10 mg | 0 Participants |
|---|
| Single-rising Dose Part - BI 1569912 20 mg | 0 Participants |
|---|
MD Part - Number of Subjects With Drug-related Adverse Events
From first drug administration until last administration of study drug plus 48 hours (REP), or 12:00 a.m. on day after subject's trial termination date, whichever occurs first, up to 16 days. · Participants
| Multiple Dose Part - Placebo | 1 Participants |
|---|
| Multiple Dose Part - 20 mg BI 1569912 | 2 Participants |
|---|
Evening PK Part - Area Under the Concentration-time Curve of BI 1569912 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
Within 3 hours (h) prior to drug administration and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 h after drug administration. · hours*nanomole/Liter
| Evening Pharmacokinetics Part - 5 mg BI 1569912 R | 892.68 ± NA hours*nanomole/Liter |
|---|
| Evening Pharmacokinetics Part - 5 mg BI 1569912 T | 817.93 ± NA hours*nanomole/Liter |
|---|
| Ratio of adjusted geometric means [%] | 91.63 (95% CI 89.46–93.84) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。